








1. Review USPSTF recommendations for the use of medications to 
prevent breast cancer in high-risk women
2. Identify breast cancer risk calculation tools
3. Recall mechanism of action of aromatase inhibitors
4. Explore a journal article supporting the use of anastrozole to prevent 
breast cancer in high-risk post-menopausal women
5. Review and apply Odds Ratios (ORs)




• Estimating breast cancer risk
• Mechanism of action:  aromatase inhibitors
• Article
• Methods
• Statistics Detour: Odds Ratios
• Results
• Discussion
• Implications for Practice
SCOPE
• We will not discuss…
• Details of estimating breast cancer risk
• Details of estimating risk of adverse effects from medications used 
to prevent breast cancer
• Use of tamoxifen, raloxifene, or non-anastrazole aromatase 
inhibitors for prevention of breast cancer
BACKGROUND
• Breast cancer is the most common nonskin cancer among 
women in the U.S. and the 2nd leading cause of cancer death
• Median age at diagnosis = 62 years
• An estimated 1 in 8 women will develop breast cancer at some 
point in their lifetime









What is the evidence behind 
use of these medications?
USPSTF RECOMMENDATIONS
USPSTF (2019)




How do we estimate risk 
for adverse effects?
ESTIMATING BREAST CANCER RISK
• Many methods available (tools vs. clinical estimation)
• USPSTF does not endorse any particular tool 
à 2 U.S. Population-based tools:  
• The National Cancer Institute Breast Cancer Risk Assessment Tool
• Breast Cancer Surveillance Consortium Risk Calculator
• Clinicians may use combination of risk factors to estimate risk
• E.g., age 65+ with 1 first-degree relative with breast cancer
USPSTF (2019)
ESTIMATING BREAST CANCER RISK
bcrisktool.cancer.gov/calculator.html tools.bcsc-scc.org/BC5yearRisk/calculator.htm
CONSIDERING RISK-REDUCING MEDICATIONS
When considering risk-reducing medications, the 
potential benefit of risk reduction of breast cancer 




When considering risk-reducing medications, the 
potential benefit of risk reduction of breast cancer 




When considering risk-reducing medications, the 
potential benefit of risk reduction of breast cancer 
must be weighed against the potential harms of 
adverse medication effects
USPSTF (2019)
• Anastrozole: an aromatase inhibitor
• Inhibits aromatase enzyme through 
reversible binding
• Blocks production of estrogen
• After menopause, residual estrogen 
production is solely from non-glandular 
sources – mostly subcutaneous fat
à Reduced risk for development of 
estrogen-responsive breast cancers
• Also reduces estrogen’s actions on other 
organs and body functions 
(bone/muscles, cardiovascular system, 
endometrium, etc.)
• Potential adverse effects include: CV 
events including stroke, myalgias, 
arthralgias, fractures, vasomotor 
symptoms
N Engl J Med (2013)




• 2 large clinical trials have studied the use of aromatase inhibitors to 
reduce risk of breast cancer in high-risk women, with favorable results 
within a 5 yr period of medication use
• MAP.3 (N Engl J Med, 2011)
• International Breast Cancer Intervention Study II (IBIS-II; Lancet, 2013)
• This article:  blinded, long-term follow-up results for the IBIS-II trial, 
which compared anastrozole with placebo
• Goal: Determine the efficacy of anastrozole for preventing breast cancer 
in the post-treatment (after 5 yr) period
Lancet (2020)
METHODS:  STUDY DESIGN
METHODS:  STUDY DESIGN




• Post-menopausal women at high risk for breast cancer
• Age 40-70
• Recruited in a 9-year period between 2003 and 2012
• From 153 breast cancer treatment centers across 18 countries
Lancet (2020)
METHODS:  INCLUSION CRITERIA
POST-MENOPAUSAL
• Age ≥60
• S/p bilateral oophorectomy
• Age <60 with a uterus and 
amenorrhea for >12 mo
• Age <60 without a uterus, with 
FSH >30 IU/L
HIGH RISK
For breast cancer, compared to the 
general population (RR = relative risk)
• Age 40-45 with RR ≥4x higher
• Age 45-60 with RR ≥2x higher
• Age 60-70 with RR ≥1.5x higher
Lancet (2020)
Lancet (2013)
How do we estimate 
breast cancer risk?
METHODS:  EXCLUSION CRITERIA
• Premenopausal
• Previous breast cancer including DCIS dx >6 mo before trial entry
• Previous invasive cancer in past 5 yr (except non-melanoma skin cancer or cervical cancer)
• Current or previous use of selective estrogen receptor modulators (SERMs) for >6 mo
• Intention to continue hormone replacement therapy
• Prophylactic mastectomy
• Evidence of severe osteoporosis (T score <-4, or >2 vertebral fractures)










METHODS:  PROCEDURES & OUTCOMES
Lancet (2020)
Anastrozole









METHODS:  PROCEDURES & OUTCOMES
Lancet (2020)
Anastrozole











- ER+ breast ca





- Deaths not due to 
breast ca
5 yr
METHODS:  PROCEDURES & OUTCOMES
Lancet (2020)
Anastrozole
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5 yr ~6 yr
METHODS:  PROCEDURES & OUTCOMES
Lancet (2020)
Anastrozole
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- ER+ breast ca
- Breast ca mortality





5 yr ~6 yr
METHODS:  PROCEDURES & OUTCOMES
Lancet (2020)
METHODS:  STATISTICAL ANALYSIS
• Intention-to-treat analysis
• Efficacy endpoints
• Hazard ratios (HRs)
• Survival curves
• Kaplan-Meier method
• Side effects and secondary outcomes





What is an Odds Ratio (OR)?
STATISTICS 
DETOUR
What is an Odds Ratio (OR)?
Odds Ratio:   A measure of association between an 
exposure and an outcome
“The odds that an outcome will occur given a particular 
exposure, compared to the odds of the outcome 
occurring in the absence of the exposure”
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What is an Odds Ratio (OR)?
Odds Ratio:   A measure of association between an 
exposure and an outcome
“The odds that an outcome will occur given a particular 
exposure, compared to the odds of the outcome 
occurring in the absence of the exposure”
OR = 1 à Exposure does not affect odds of outcome
OR > 1 à Exposure assoc with higher odds of outcome
OR < 1 à Exposure assoc with lower odds of outcome
STATISTICS 
DETOUR
Odds Ratio:   “The odds that an outcome will occur given a 
(OR) particular exposure, compared to the odds of the 






a  =  exposed cases
b  =  exposed non-cases
c  =  unexposed cases
d  =  unexposed non-cases
STATISTICS 
DETOUR
Odds Ratio:   “The odds that an outcome will occur given a 
(OR) particular exposure, compared to the odds of the 






a  =  exposed cases
b  =  exposed non-cases
c  =  unexposed cases
d  =  unexposed non-cases
OR  = 
exposed cases / unexposed cases
exposed non-cases / unexposed non-cases
OR  = 
a / c
b / d





Odds Ratio:   “The odds of having a fracture in the anastrozole group, 






a  =  exposed cases
b  =  exposed non-cases
c  =  unexposed cases




• Intention to treat:  
• All women (n = 3864) randomly assigned to anastrozole (n = 1920) vs 
placebo (n = 1944) were included in analysis 
• Treatment adherence for full 5 yr:  75% for anastrozole, 77% for placebo
• After the initial 5-yr treatment period, 3704 (~96%) women were still 
at risk of developing breast cancer
• Median follow-up was 131 months (10 yr, 11 mo)








Hazard ratio: measure of the effect of an 
intervention on an outcome of interest over time
BREAST CANCERS
49% reduction in all breast cancer
à 61% ↓ within first 5 yrs
à 37% ↓ during follow-up
54% reduction in invasive ER+ ca
à 61% ↓ within first 5 yrs
à 48% ↓ during follow-up
Significant reduction in DCIS
Lancet (2020)
BREAST CANCERS
After 12 yr of follow-up, 
estimated risk of developing 
breast cancer:
- 8.8% in placebo group
- 5.3% in anastrozole group
Number needed to treat 
(NNT) for 5 yr to prevent one 






28% reduction in all non-breast cancers
à Mostly driven by a reduction in 
the incidence of non-melanoma 
skin cancer
à No significant effect on other 
cancers
Interestingly, no reduction in 
endometrial cancer (estrogen 
thought to be a major driver)
MAJOR ADVERSE EVENTS
No significant effect seen on any major adverse event
- No excess of fractures




Odds Ratio:   “The odds of having a fracture in the anastrozole group, 






a  =  exposed cases
b  =  exposed non-cases
c  =  unexposed cases





Odds Ratio:   “The odds of having a fracture in the anastrozole group, 






a  =  exposed cases
b  =  exposed non-cases
c  =  unexposed cases
d  =  unexposed non-cases
OR  = 
ad 
bc = 1.04 (95% CI 0.88–1.22)
No significant increase in fracture risk in patients 




No significant difference in deaths between anastrozole and placebo groups, 
either from breast cancer or other causes
- Numbers are small overall
à Will need longer follow-up to determine whether anastrozole affects breast 
cancer and other cause mortality
Lancet (2020)
DISCUSSION
• Study supports the use of anastrozole in breast cancer prevention for 
high-risk post-menopausal women  
• Benefits of anastrozole for breast cancer risk reduction extend beyond 
the 5-yr treatment period
• NNT during first 12 yr of follow-up for anastrozole = 29
• NNT during first 12 yr of follow-up for tamoxifen = 58
• Reduction in breast cancer seen was mostly for ER+ cancers
• Interestingly, also saw reduction in receptor-negative cancers 
à needs further validation
Lancet (2020)
DISCUSSION
• Too early to glean meaningful information about breast cancer-related 
deaths à need longer follow-up
• No excess side effects identified with longer follow-up
• 11% excess of fractures during the active treatment period did not continue 
after 5 yr of follow-up
• Did not measure minor adverse effects after the 5-yr treatment period
Lancet (2020)
LIMITATIONS
• How diverse was the patient population?  External validity?  
No mention of race/ethnicity, though was an international study
• Duration of follow up
• Need longer-term data re: mortality
• Did not measure minor adverse effects in follow-up period
• Some minor effects may have important implications for QOL 
(e.g., hot flashes, arthralgias)
• Need better tools to evaluate risk for breast cancer and risk for 
adverse effects of medications to prevent breast cancer
SUMMARY
• For women aged ≥35 yr at increased risk for breast cancer, USPSTF 
recommends we offer to prescribe risk-reducing medications, such as 
tamoxifen, raloxifene, or aromatase inhibitors, to patients who are at 
low-risk for adverse effects of this treatment
• Breast cancer risk calculation tools:  
NCI Breast Cancer Risk Assessment Tool & BSCS risk calculator
• Aromatase inhibitors block the production of estrogen, thereby 
reducing risk for breast cancer (particularly ER+ cancer)
• Cuzick et al (2020) study provides longer-term data to support the use 
of anastrozole to prevent breast cancer in high-risk post-menopausal 
women
HOW WILL THIS KNOWLEDGE 
INFLUENCE YOUR PRACTICE? 
IMPLICATIONS FOR PRACTICE?
• More careful history to assess women ≥35 for risk of breast cancer
• Risk factors:
• Age, menarche, parity, age of first birth, race/ethnicity, first- and second-degree relatives with hx of 
breast ca, age of relatives’ dx, prior breast bx, breast density
• Consider use of risk calculator
• Consider need for BRCA testing in women with strong FHx
• Think about these issues at well adult visits, when ordering mammograms, and even 
before age 40!
• If considering medication to prevent breast cancer, also consider risk for adverse 
effects of medication:
• History of or risk for osteoporosis, endometrial cancer, VTE, CV events, etc.
• Tamoxifen, raloxifene, and aromatase inhibitors have overlapping yet somewhat 
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